Display options
Cite
Cao X, Wen ZS, Wang XD, et al. The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies. J Cancer. 2017;8(13):2532-2541doi: 10.7150/jca.19750.
Cao, X., Wen, Z. S., Wang, X. D., Li, Y., Liu, K. Y., & Wang, X. (2017). The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies. Journal of Cancer, 8(13), 2532-2541. https://doi.org/10.7150/jca.19750
Cao, Xun, et al. "The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies." Journal of Cancer vol. 8,13 (2017): 2532-2541. doi: https://doi.org/10.7150/jca.19750
Cao X, Wen ZS, Wang XD, Li Y, Liu KY, Wang X. The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies. J Cancer. 2017 Aug 02;8(13):2532-2541. doi: 10.7150/jca.19750. eCollection 2017. PMID: 28900491; PMCID: PMC5595083.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2017 Aug 02;8(13):2532-2541. doi: 10.7150/jca.19750. eCollection 2017.

The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies.

Journal of Cancer

Xun Cao, Zhe-Sheng Wen, Xu-Dong Wang, Yong Li, Kui-Yuan Liu, Xin Wang

Affiliations

  1. Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China.
  2. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.

PMID: 28900491 PMCID: PMC5595083 DOI: 10.7150/jca.19750

Abstract

Preclinical investigations have revealed an anti-cancer effect of metformin. Several studies of metformin treatment have demonstrated the improved clinical outcomes of lung cancer patients with diabetes; however, the results have been inconsistent among studies. Our systematic review and meta-analysis aimed to summarize the up-to-date effects of metformin on diabetic lung cancer patients. A systematic search was performed for studies published. Then, these studies were evaluated for inclusion, and relevant data was extracted. The summary risk estimates for the associations of metformin treatment with overall survival (OS) and progression-free survival (PFS) were analyzed using random/fixed-effects models. Analyses stratified by histological type were also conducted. Based on the 10 studies included in our analysis, metformin treatment was found to significantly improve survival, corresponding to reductions of 23% and 47% in OS [hazard ratio (HR)=0.77, 95% confidence interval (95%CI)=0.66-0.9,

Keywords: Diabetes; Lung cancer; Meta-analysis.; Metformin; Survival

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

  1. Cancer Res. 2006 Nov 1;66(21):10269-73 - PubMed
  2. Cell Cycle. 2009 Jul 1;8(13):2031-40 - PubMed
  3. J Clin Oncol. 2009 Jul 10;27(20):3297-302 - PubMed
  4. Stat Med. 2002 Jun 15;21(11):1539-58 - PubMed
  5. J Thorac Dis. 2015 Mar;7(3):346-55 - PubMed
  6. CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21 - PubMed
  7. Am J Respir Crit Care Med. 2015 Feb 15;191(4):448-54 - PubMed
  8. J Clin Oncol. 2002 Jan 1;20(1):42-51 - PubMed
  9. BMC Cancer. 2016 Aug 12;16:633 - PubMed
  10. Diabetes Care. 2012 Feb;35(2):299-304 - PubMed
  11. Cancer Lett. 2015 Dec 1;369(1):97-102 - PubMed
  12. Drug Discov Today. 2013 May;18(9-10):495-501 - PubMed
  13. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  14. Clin Transl Oncol. 2015 Oct;17 (10 ):819-24 - PubMed
  15. J Thorac Cardiovasc Surg. 2016 Jul;152(1):55-61.e1 - PubMed
  16. Cancer Res. 2007 Nov 15;67(22):10804-12 - PubMed
  17. Cancer Prev Res (Phila). 2012 Apr;5(4):536-43 - PubMed
  18. J Thorac Oncol. 2015 Jul;10(7):990-1003 - PubMed
  19. Breast Cancer Res Treat. 2015 Apr;150(2):427-37 - PubMed
  20. Lancet. 1992 Jan 4;339(8784):1-15 - PubMed
  21. Curr Drug Saf. 2013 Nov;8(5):357-63 - PubMed
  22. Endocr Rev. 2009 Oct;30(6):586-623 - PubMed
  23. Am J Epidemiol. 2008 Feb 15;167(4):492-9 - PubMed
  24. Lung Cancer. 2016 Apr;94:35-9 - PubMed
  25. Nat Rev Cancer. 2008 Dec;8(12):915-28 - PubMed
  26. Radiother Oncol. 2016 Mar;118(3):453-9 - PubMed
  27. BMC Cancer. 2012 Sep 14;12:410 - PubMed
  28. Front Oncol. 2013 Dec 25;3:313 - PubMed
  29. Nat Med. 2014 Jun;20(6):591-3 - PubMed
  30. Asian Pac J Cancer Prev. 2015;16(15):6621-6 - PubMed
  31. Cancer Res. 2009 Oct 1;69(19):7507-11 - PubMed
  32. Curr Med Res Opin. 2006;22 Suppl 2:S27-37 - PubMed
  33. Cell Cycle. 2009 Jan 1;8(1):88-96 - PubMed
  34. Endocr Relat Cancer. 2008 Sep;15(3):833-9 - PubMed
  35. J Am Med Inform Assoc. 2015 Jan;22(1):179-91 - PubMed
  36. Cancer. 2011 Nov 15;117(22):5103-11 - PubMed
  37. Cell Cycle. 2009 Mar 15;8(6):909-15 - PubMed
  38. Int J Cancer. 2017 Jul 15;141(2):254-263 - PubMed
  39. Trends Pharmacol Sci. 2013 Sep;34(9):508-17 - PubMed
  40. Int J Cancer. 2016 Jan 15;138(2):369-79 - PubMed
  41. Nat Clin Pract Oncol. 2005 Jan;2(1):48-53 - PubMed
  42. J Clin Oncol. 2013 Sep 1;31(25):3069-75 - PubMed
  43. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  44. Tumour Biol. 2015 Sep;36(10):8101-6 - PubMed
  45. Cell Cycle. 2009 May 15;8(10 ):1633-6 - PubMed
  46. J Mol Endocrinol. 2012 Mar 29;48(3):R31-43 - PubMed

Publication Types